Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) announced expanded collaboration with NVIDIA at RSNA 2025 to embed NVIDIA accelerated computing across CT, MRI, ultrasound, cardiac, and mammography solutions.
Key highlights include Photonova Spectra PCCT (510(k) pending) claiming up to 50x more data throughput, SIGNA Bolt and SIGNA Sprint MRI platforms using NVIDIA GPU-accelerated reconstruction, Pristina Recon DL for 3D mammography, and Vivid Pioneer ultrasound with dual professional NVIDIA GPUs. Early-stage autonomous X-ray and ultrasound concepts are being explored with NVIDIA Isaac and Holoscan.
GE HealthCare (Nasdaq: GEHC) unveiled Allia Moveo, a compact, cable-free C-arm image-guiding solution for the interventional suite designed to increase mobility, patient access and workflow efficiency. The system features a slim, wide-bore C-arm intended to enable cone beam CT (CBCT) for a broader patient range, ergonomic controls accessible from nearly any position, AI-powered and augmented guidance tools, and SmartMove to reposition and restore the C-arm at the press of a button. Allia Moveo supports multi-modality integrations and is FDA 510(k) pending. Availability may vary by region; GE HealthCare will showcase the platform at RSNA 2025 (booth #7334).
GE HealthCare (Nasdaq: GEHC) will present at RSNA 2025 on November 30, 2025, showcasing more than 40 technology innovations across imaging devices, radiopharmaceuticals, cloud and AI solutions.
Key disclosures include $3B invested in R&D since 2022; the FDA-approved PET MPI agent Flyrcado (flurpiridaz F 18) with CMS traditional pass-through effective Apr 1, 2025; Photonova Spectra photon-counting CT (510(k) pending); next‑gen SIGNA MRI systems (510(k) pending); and a claim of 100 FDA-authorized AI-enabled solutions.
GE HealthCare (Nasdaq: GEHC) announced on November 30, 2025 the unveiling of next‑generation SIGNA MRI technology and submitted 510(k) filings to the U.S. FDA seeking clearance. New systems include SIGNA Bolt (a 3.0T high‑field wide‑bore system) and SIGNA Sprint with Freelium (a 1.5T, purposefully helium‑free/ventless design with <1% helium usage). Both run on the AI‑driven SIGNA One workflow platform aimed at improving exam efficiency, patient setup, and imaging reconstruction. The announcement emphasizes sustainability, installation flexibility, and AI‑enabled workflow automation while noting regulatory clearance is pending.
GE HealthCare (Nasdaq: GEHC) announced FDA Premarket Authorization for Pristina Recon DL, a deep learning 3D mammography reconstruction application that enhances image sharpness, reduces artifacts, and preserves patient dose. The technology uses two sequential deep learning models plus iterative reconstruction and NVIDIA RTX acceleration to deliver fast, high-fidelity DBT images in the exam room. Clinical validation cited a 99.1% radiologist preference for overall image quality and improved detection of microcalcifications and masses. The feature is upgradable on Pristina Via and supports workflow and patient‑experience improvements.
GE HealthCare (Nasdaq: GEHC) introduced Genesis™ Radiology Workspace, a cloud-first radiology solution built to unify the user experience, streamline workflows, and enable diagnosticians to read from virtually anywhere.
The platform centers on Genesis™ View (510(k) pending; not available for sale in the United States), a zero-footprint viewer that offers high-performance 2D/3D visualization, embedded AI tools, FHIRcast interoperability, and direct access to Advanced Visualization apps. The suite integrates with GE HealthCare’s Genesis cloud portfolio and will be shown at RSNA 2025 (Nov. 30–Dec. 4) in Chicago, booth 7334.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the fourth quarter of 2025. The dividend is payable on February 13, 2026 to shareholders of record as of January 9, 2026.
GE HealthCare (NYSE:GEHC) announced on November 24, 2025 the submission of a 510(k) to the U.S. FDA for Photonova™ Spectra, a next‑generation photon‑counting CT (PCCT) system built on GE HealthCare’s proprietary Deep Silicon detector technology. Photonova Spectra offers 8‑bin energy resolution, up to 50x more data versus conventional CT, a 0.23s rotation speed, wide detector coverage and UHD spectral imaging designed for neurology, oncology, musculoskeletal, thoracic and cardiac exams. The system is 510(k)‑pending, not CE marked and not available for sale in the U.S., Europe, Canada or other regions. GE HealthCare highlights NVIDIA partnership for accelerated computing and AI‑enabled reconstruction to support on‑demand spectral images and a one‑scan workflow.
GE HealthCare (Nasdaq: GEHC) agreed to acquire Intelerad for $2.3 billion in cash, aiming to create a cloud-first, AI-enabled enterprise imaging platform across inpatient and outpatient settings.
The deal is expected to close in H1 2026, accelerate GE HealthCare’s SaaS and recurring-revenue mix, and support the company’s goal to triple cloud-enabled offerings by 2028.
Intelerad is forecast to deliver ~$270 million revenue in the first full year (≈90% recurring) and an adjusted EBITDA margin >30%; GEHC expects immediate top-line and EBIT margin accretion, short-term slight EPS dilution due to financing, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) announced that Cardiovascular Associates of America (CVAUSA) plans to expand use of FDA‑approved PET radiotracer Flyrcado (flurpiridaz F 18) across ~25 sites after a successful two‑week, 21‑patient pilot at Cardiovascular Medicine in Davenport, Iowa.
The network performs about 85,000 cardiac PET procedures annually, and GE highlighted new distribution support with CDL Nuclear Technologies and inclusion of flurpiridaz F 18 in a co‑published international procedure standard for cardiac PET MPI.